Showing results (351-360 of 376) with videos related to

Sort By:
Pageof 38
The Journal of Pathology|September 19, 2006
Evolution of VHL tumourigenesis in nerve root tissueA O Vortmeyer, M G B Tran, W Zeng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 1997
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's diseaseD L Longo, E Glatstein, P L Duffey, et al.
Blood|August 29, 2000
European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytesI Anagnostopoulos, M L Hansmann, K Franssila, et al.
Blood|February 15, 1997
Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosisM C Sneller, J Wang, J K Dale, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1983
Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemiaS J Korsmeyer, W C Greene, J Cossman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma)T Rüdiger, E S Jaffe, G Delsol, et al.
Leukemia|April 27, 2013
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyS E M Herman, X Sun, E M McAuley, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2001
ANX7, a candidate tumor suppressor gene for prostate cancerM Srivastava, L Bubendorf, V Srikantan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann, E S Vitetta, D Headlee, et al.
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II studyD L Longo, P L Duffey, J G Gribben, et al.
Pageof 38